Home/Filings/4/0001209191-21-014736
4//SEC Filing

Parini Michael 4

Accession 0001209191-21-014736

CIK 0000875320other

Filed

Feb 25, 7:00 PM ET

Accepted

Feb 26, 4:18 PM ET

Size

12.1 KB

Accession

0001209191-21-014736

Insider Transaction Report

Form 4
Period: 2021-02-24
Transactions
  • Tax Payment

    Common Stock

    2021-02-24$217.57/sh2,416$525,64933,865 total
  • Sale

    Common Stock

    2021-02-25$211.58/sh646$136,68133,219 total
  • Sale

    Common Stock

    2021-02-25$213.04/sh1,348$287,17831,871 total
  • Sale

    Common Stock

    2021-02-25$214.28/sh680$145,71031,191 total
  • Sale

    Common Stock

    2021-02-25$216.26/sh354$76,55630,837 total
Footnotes (6)
  • [F1]Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1.
  • [F2]Open market sales reported on this line occurred at a weighted average price of $211.58 (range $211.34 to $211.91).
  • [F3]Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
  • [F4]Open market sales reported on this line occurred at a weighted average price of $213.04 (range $212.76 to $213.68).
  • [F5]Open market sales reported on this line occurred at a weighted average price of $214.28 (range $213.90 to $214.69).
  • [F6]Open market sales reported on this line occurred at a weighted average price of $216.26 (range $215.79 to $216.76).

Issuer

VERTEX PHARMACEUTICALS INC / MA

CIK 0000875320

Entity typeother

Related Parties

1
  • filerCIK 0001661567

Filing Metadata

Form type
4
Filed
Feb 25, 7:00 PM ET
Accepted
Feb 26, 4:18 PM ET
Size
12.1 KB